Drug developer Vectura has announced that the first three QVA149 Phase III studies in the treatment of chronic obstructive pulmonary disease (COPD) all met their primary endpoints.
The results demonstrate the potential of the product as a treatment for COPD.
Chief Executive Dr Chris Blackwell said: "Achieving the primary endpoints in all three of the Phase III studies gives us confidence that QVA149 could be the first product of this type to provide benefit to patients with COPD in a multi-billion dollar market that is still growing.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"QVA149 is an investigational inhaled, once-daily, fixed dose combination of the long acting beta2-agonist (LABA) indacaterol, and the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide (NVA237). Data from the clinical trial program, examining QVA149 in a number of settings, will be submitted for presentation to a major medical congress later this year."
The share price rose 5.07% to 57.00p by 11:43.
NR
